In a landmark announcement, the World Health Organization (WHO) has recommended the use of the first-ever malaria vaccine for children. WHO Director-General Tedros Adhanom Ghebreyesus endorsed the RTS,S/AS01 malaria or Mosquirix – a vaccine developed by British drugmaker GlaxoSmithKline (GSK).

The WHO has recommended extensive use of the RTS,S/AS01  vaccine among children in Sub-Saharan Africa and other regions with moderate to high malaria transmission. The vaccine acts against the deadliest malaria transmission parasite, P. falciparum, which is prevalent in Africa. The symptoms of malaria are–fever, headaches, and muscle pain, then cycles of chills, fever, and sweating.

According to Tedros, ” RTS,S malaria vaccine – more than 30 years in the making – changes the course of public health history. This vaccine is a gift to the world”.

The WHO said in a statement it was recommending the widespread application of the vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.

Many vaccines exist against viruses and bacteria, but this was the first time that the WHO recommended broad use of a vaccine against a human parasite.

According to the latest World Malaria Report, there were an estimated 229 million cases of malaria globally in 2019, with the WHO African region accounting for 94 per cent of all cases and deaths.

A child under five years old dies of malaria every two minutes, according to UNICEF estimates, while WHO says that malaria is responsible for 260,000 deaths each year in children under five in Africa.

The third phase of clinical trials revealed that the vaccine was 50 per cent efficacious in preventing malaria in children aged between five and 17 months. The vaccine is given in three doses between these ages, with a fourth dose about 18 months later.

According to Reuters news agency, experts said the challenge now would be mobilising financing for production and distribution of the vaccine. GSK has to date committed to producing 15 million doses of Mosquirix annually up to 2028 at a cost of production plus no more than 5% margin.

A global market study led by the WHO this year projected demand for a malaria vaccine would be 50 to 110 million doses per year by 2030 if it is deployed in areas with moderate to high transmission of the disease.

Resources:
https://www.livemint.com/science/health/who-approves-world-s-first-malaria-vaccine-11633573233450.html

More News
Major Regulatory Changes in 2025
News · 02/05/2025

In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.

READ MORE
Technologies And Strategies Reshaping Regulatory Trends
News · 02/05/2025

The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.

READ MORE
Biomanufacturing proliferates in chemicals
News · 31/03/2025

In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?

READ MORE
New Trump tariffs worry North American chemical industries
News · 31/03/2025

High duties on imports from Canada, Mexico and China raise problems for international supply chains.

READ MORE
Advanced Drug Delivery Systems
News · 01/03/2025

Advanced Drug Delivery Systems Market, valued at USD 234.84 billion in 2023, is on a trajectory of significant growth, projected to reach USD 352.01 billion by 2032

READ MORE
US FDA Bans Food Dye Red No.3
News · 01/03/2025

The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.

READ MORE
Emerging Trends in Microsphere Technology
News · 01/02/2025

Targeted drug delivery revolutionises treatment by focusing medications on specific tissues, reducing the impact on healthy cells. Scientists enhance this precision with carriers like microspheres and nanoparticles, controlling release and absorption. Microspheres, made from biodegradable proteins or polymers, sustain drug release, making them ideal for targeted therapies, especially in oncology. Beyond drug delivery, microspheres open new possibilities across industries—from next-gen coatings to thermal insulation. With tailored sizes, shapes, and materials, they drive advancements in pharmaceuticals, advanced materials, and more.

READ MORE
US FDA proposes mandatory Asbestos testing in Cosmetics with Talc
News · 01/02/2025

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos. The FDA noted that this move aims to protect consumers from potential harm posed by asbestos, a known carcinogen linked to serious illnesses such as lung and ovarian cancers.

READ MORE
Chinese New Year affects Asian freight traffic
News · 20/01/2025

As one of the most significant holidays in China, Chinese New Year (CNY) profoundly impacts global shipping, logistics, and supply chains. Scheduled to begin on January 29, 2025, this festive period lasts up to two weeks, with many factories, ports, and businesses shutting down or operating with limited staff. Understanding the implications of CNY on your supply chain is critical to avoid disruptions and ensure seamless operations.

READ MORE